This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

ADVENTRX Announces Appointment Of Chief Medical Officer

Stocks in this article: ANX

SAN DIEGO, Aug. 14, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Santosh J. Vetticaden, M.D., Ph.D., will join the Company as Chief Medical Officer and Senior Vice President.

Dr. Vetticaden has more than 25 years of experience in drug development and medicine.  His experience spans a variety of therapeutic areas, including anticoagulation, hemophilia, anti-infectives and rheumatology/inflammation.  He has directed and managed the clinical development of both large and small molecules, from protocol design to execution of multi-center, global clinical trials. 

Dr. Vetticaden has held several senior level positions leading drug development across phase 1 through phase 4 trials at biotech and large pharmaceutical companies.  Most recently, he served as Senior Vice President and Chief Medical and Development Officer at Cubist Pharmaceuticals, Inc., where his tenure was highlighted by successful phase 2 trials and advancing multiple drugs into phase 3.  At Cubist, he also played a significant role in the development and execution of new business strategy that resulted in significant product pipeline expansion.  Prior to joining Cubist, Dr. Vetticaden was Senior Vice President and Chief Medical Officer at Maxygen, Inc., where he had responsibilities and oversight for clinical development and regulatory affairs for all of the company's development programs, including Maxy-VIIa, which he progressed from the non-clinical stage through a phase 1 study in hemophilia, resulting in its outlicense to Bayer.  Before Maxygen, he held senior roles in drug development at Scios, Inc., a subsidiary of Johnson & Johnson, Aventis Pharmaceuticals (now Sanofi) and the Whitehall-Robins Healthcare division of American Home Products Corporation (now Pfizer).  Dr. Vetticaden has a Ph.D. in the areas of pharmacokinetics and pharmacodynamics from Virginia Commonwealth University; a M.D from the University of Maryland and completed a residency in internal medicine at the Baylor College of Medicine. 

"I have been closely involved in the development and lifecycle management of several transformative products, including Lovenox®, Cubicin®, Xarelto®, and Natrecor®, and I look forward to playing a key role in successful development of ANX-188, which has the potential to treat many serious and life-threatening diseases and conditions," said Dr. Vetticaden. "With the phase 3 study in sickle cell disease anticipated to begin this year, joining ADVENTRX is an opportunity to have a potentially transformational impact in the treatment of diseases and conditions associated with microvascular dysfunction."

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,365.86 -14.55 -0.09%
S&P 500 1,898.57 +11.81 0.63%
NASDAQ 4,301.5930 +43.1550 1.01%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs